HFE H63D

Finding H63D on a genetic report can sound like a diagnosis of hemochromatosis. It usually has much less significance. One copy alone rarely contributes to clinically important iron overload, and most people with two copies never develop iron-related disease.

HFE genotyping is an established clinical tool, but H63D by itself is a weak predictor of disease. Its significance depends on your other HFE variants, particularly C282Y, and whether you have evidence of excess iron. An H63D result alone doesn't establish that iron is accumulating or damaging your liver.

What the Variant Changes

Your body has no regulated way to excrete large amounts of excess iron, so it controls iron mainly through absorption and recycling. Hepcidin is a liver hormone that reduces iron absorption from the gut and iron release from storage cells. The HFE protein helps the liver respond to circulating iron and regulate hepcidin production.

H63D replaces histidine with aspartic acid at position 63 of the HFE protein. These are two of the building blocks used to make proteins. In laboratory cell experiments, the altered protein still reached the cell surface and bound the transferrin receptor, but it changed how that receptor interacted with iron-carrying transferrin. C282Y disrupted the protein's movement to the cell surface much more severely.

Transferrin saturation is the share of your blood's iron-carrying protein that is loaded with iron. H63D can raise this measure slightly. Ferritin helps assess stored iron, but it also rises with inflammation and liver injury, so it cannot establish iron overload by itself.

How Common It Is

H63D is common, particularly in people with European ancestry. A nationally representative US survey estimated that about one in four people carried at least one copy, including about 2% with two copies. The often-quoted 13.5% figure from that survey describes the share of gene copies carrying H63D, not the share of people who carry it.

Frequency varies substantially across ancestry groups. Having two H63D copies is more common than having two C282Y copies, even though C282Y homozygosity accounts for most HFE-related hemochromatosis in people of northern European ancestry.

Reading Your Genotype

This result identifies whether you carry zero, one, or two copies of H63D. C282Y is a separate result. Having one H63D copy and one C282Y copy on opposite copies of the HFE gene is called compound heterozygosity.

Iron Overload Risk

In a population study of about 2,500 Australian adults without C282Y, H63D was associated with higher transferrin saturation, while ferritin did not differ significantly by genotype. About 9% of men with two H63D copies had both raised transferrin saturation and raised ferritin, but the study found no association with clinically significant iron overload.

A separate study followed people with a single H63D copy for about 12 years and found no documented iron overload. For compound heterozygotes, a study drawn from a larger Australian cohort found documented iron overload-related disease in 1 of 82 men and none of 95 women assessed after roughly 12 years.

Clinic populations give different estimates because people are often referred after abnormal blood tests. In a Canadian series of H63D homozygotes referred for genetic testing, 4 of 60 people with follow-up information met criteria for documented iron overload. Only one had iron overload-related disease. These findings show that occasional cases occur, but they do not provide a reliable lifetime percentage for everyone with two H63D copies.

Long-Term Health and Lifespan

Large population studies are reassuring about H63D. They include people identified through research genotyping, which reduces the bias that comes from studying only people referred to an iron clinic.

The UK study estimated outcomes through age 80; it did not follow every participant until that age. Men with two C282Y copies had about 29% higher mortality during follow-up, a finding that should not be applied to H63D.

An earlier UK analysis found a small association between compound heterozygosity and hip replacement in men, but it did not remain statistically significant after accounting for the many comparisons made. These population findings cannot exclude every individual case, especially when iron overload is already documented.

Other Conditions That Affect Iron

Fatty liver disease, heavy alcohol use, hepatitis, and some inherited blood disorders can alter iron measures independently of H63D. Finding the variant alongside one of these conditions does not establish that it caused or worsened the condition.

A meta-analysis covering several liver diseases found modestly higher odds of fatty liver disease among H63D carriers, about a quarter higher than among non-carriers. It found no statistically significant association with cirrhosis. These were observational comparisons, and the association does not prove that H63D causes fatty liver.

In one older study of chronic hepatitis C, a single H63D copy was associated with about three times the odds of cirrhosis. The estimate was imprecise, and another study did not find an association between H63D and advanced liver scarring. This evidence does not establish a special monitoring schedule based on H63D alone.

Beta-thalassemia trait is an inherited change in hemoglobin production that usually causes small red blood cells and sometimes mild anemia. One study found higher ferritin in people who had both this trait and two H63D copies. Only four participants had that combination, so the finding is too small to predict how much iron an individual will accumulate.

Blood Pressure, Cancer, and Other Associations

In an ARIC analysis, high blood pressure was more common among people with H63D. At study visits, its prevalence was 2 to 4 percentage points higher with one copy and 4 to 7 percentage points higher with two copies. These figures describe differences in how many people had hypertension at each visit. Over about 25 years, the study did not detect increased cardiovascular events or substantial changes in heart structure.

A study within the European EPIC cohort associated each H63D copy with about 32% higher odds of stomach cancer. The strongest association was with the intestinal tissue subtype. A separate analysis by location found an association with cancers outside the upper stomach. This single study does not establish that H63D causes stomach cancer or justify additional cancer screening based on the variant.

A meta-analysis found no significant association between H63D and the chance of developing multiple sclerosis in the European-ancestry populations studied.

Possible Benefits Remain Research Findings

A meta-analysis of 586 endurance athletes and 1,416 controls found that athletes had about twice the odds of carrying H63D. A small subgroup of male athletes also showed an association with higher aerobic capacity. This does not establish that the variant improves your performance or that genetic testing should guide training.

In a study of celiac disease, people with H63D had higher hemoglobin and iron measures than those without HFE variants. That suggests a possible advantage when iron absorption is impaired, but it does not guarantee protection from iron-deficiency anemia.

When Results Can Be Misleading

Genotyping can identify the variant accurately while its medical significance is overstated. In ten years of laboratory proficiency surveys, genotyping errors occurred in about 0.7% of submitted HFE results. Interpretation errors were more common. Those historical survey figures describe participating laboratories collectively, not the accuracy of an individual result.

• Limited coverage: an H63D result covers this specific variant. A negative result does not exclude C282Y, other HFE variants, or changes in other iron-regulating genes.
• Ancestry: variant frequencies and the causes of inherited iron overload differ across populations. Most large H63D outcome studies involved people of European ancestry.
• Uncertain findings on broader sequencing: broader genetic testing can find changes whose health effects are unclear. A variant of uncertain significance does not establish a diagnosis or justify iron-removal treatment.
• Donor or tumor DNA: after a donor bone marrow or stem-cell transplant, blood DNA can reflect the donor's genotype. A finding from tumor testing also needs confirmation in a suitable non-tumor sample before it is treated as inherited.
• Consumer reports: a consumer result can identify the same variant, but confirmation in a clinical laboratory is appropriate before it changes treatment or family testing, particularly when the finding comes from raw-data interpretation.

A Result You Get Once

Your inherited H63D genotype is permanent. Routine repeat genotyping adds no information; confirmation is useful when the original call or sample identity is in doubt. The ongoing value comes from interpreting the result alongside your health history and any iron measurements.

A single H63D copy with normal iron studies generally does not require scheduled iron testing solely because of the genotype. For compound heterozygotes, annual iron studies are a reasonable option, particularly in families with diagnosed hemochromatosis. Follow-up can be adjusted to previous results and other risk factors. Two H63D copies alone do not establish a universal testing interval.